SCINEURO
SciNeuro is a biotechnology company focused on developing innovative medicines for patients with central nervous system diseases.
SCINEURO
Industry:
Biopharma Biotechnology Neuroscience
Founded:
2020-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.scineuro.com
Total Employee:
11+
Status:
Active
Total Funding:
100 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Euro
Similar Organizations
Sagimet Biosciences
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Positive Sequence Biology
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sequoia Capital China
Sequoia Capital China investment in Series A - SciNeuro
ARCH Venture Partners
ARCH Venture Partners investment in Series A - SciNeuro
Zoo Capital
Zoo Capital investment in Series A - SciNeuro
Lilly Asia Ventures
Lilly Asia Ventures investment in Series A - SciNeuro
General Atlantic
General Atlantic investment in Series A - SciNeuro
Boyu Capital
Boyu Capital investment in Series A - SciNeuro
TF Capital
TF Capital investment in Series A - SciNeuro
Official Site Inspections
http://www.scineuro.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "SciNeuro"
SciNeuro - Crunchbase Company Profile & Funding
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged …See details»
Pipeline - SciNeuro Pharmaceuticals
Prior to joining SciNeuro, she served in roles of increasing responsibility at GSK R&D China, where she grew the organization from 1 to 500 employees. She brings robust experience in …See details»
SciNeuro - Contacts, Employees, Board Members, Advisors & Alumni
Organization. SciNeuro . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Advisor Profiles 3. Contacts 15. About. SciNeuro has 2 …See details»
Startup Grabs $100 Million to Focus on China’s Untapped
Dec 8, 2020 SciNeuro will focus on key central nervous system (CNS) diseases and plans a mix of internal R&D and strategic partnerships, to develop its pipeline. Li feels like they are the first …See details»
SciNeuro - Funding, Financials, Valuation & Investors - Crunchbase
SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Search Crunchbase. ... How much funding has this …See details»
SciNeuro Pharmaceuticals Launches to Bring Innovative …
Dec 8, 2020 SciNeuro Pharmaceuticals, focused on developing innovative medicines for patients with central nervous system (CNS) diseases, today announced its launch and a $100 million …See details»
SciNeuro Pharmaceuticals Launches to Bring Innovative ... - Nasdaq
Dec 8, 2020 SciNeuro Pharmaceuticals, focused on developing innovative medicines for patients with central nervous system diseases, today announced its launch and a $100 million Series A …See details»
About Us - SciNeuro Pharmaceuticals
Prior to joining SciNeuro, she served in roles of increasing responsibility at GSK R&D China, where she grew the organization from 1 to 500 employees. She brings robust experience in …See details»
SciNeuro Pharmaceuticals Launches to Bring Innovative …
Dec 8, 2020 SHANGHAI--(BUSINESS WIRE)--SciNeuro Pharmaceuticals (www.scineuro.com), focused on developing innovative medicines for patients with central nervous system (CNS) …See details»
Deciphering the enigma of brain disease - Nature
SciNeuro is focused on developing drugs on three key disease pathways—neurovascular inflammation, proteinopathy and immune response. “Focusing on the fundamental …See details»
SciNeuro Pharmaceuticals Launches to Bring Innovative …
Dec 8, 2020 Lilly Asia Ventures Fund and Arch Venture Partners co-lead $100M Series A financing to advance the establishment of a robust and innovative CNS pipeline SHANGHAI – …See details»
SciNeuro completes dosing in its Phase 1 clinical trial of SNP318, …
Nov 30, 2023 SciNeuro Pharmaceuticals, a clinical stage biotech company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's Disease (AD) …See details»
SciNeuro Pharmaceuticals Announces a License and Option …
Jun 1, 2022 SciNeuro Pharmaceuticals is an innovation-driven, neuroscience-focused biopharmaceutical company with an established pipeline of novel therapeutic candidates to …See details»
Deciphering the enigma of brain disease - Nature
Recent SciNeuro phase 1 data have shown that SNP318 is significantly more potent than earlier Lp-PLA2 inhibitors and is able to efficiently pen-etrate the central nervous system, allowing it toSee details»
Novel Therapeutic Antibodies for CNS Diseases Collaboration
Feb 15, 2022 SciNeuro Pharmaceuticals is an innovation-driven, neuroscience-focused biopharmaceutical company with corporate and R&D facilities located in China and the United …See details»
SciNeuro completes dosing in its Phase 1 clinical trial of SNP318, …
Nov 30, 2023 SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in …See details»
SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp …
Apr 12, 2023 SciNeuro Pharmaceuticals is an innovation-driven, neuroscience-focused biopharmaceutical company with an established pipeline of novel therapeutic candidates to …See details»
SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on …
Oct 26, 2021 SciNeuro Pharmaceuticals is a leading neuromedicine company focused on elevating the standard of care for patients suffering from neurological diseases. With R&D …See details»
SciNeuro Pharmaceuticals Announces a License and Option …
Jun 1, 2022 Prior to joining SciNeuro, she served in roles of increasing responsibility at GSK R&D China, where she grew the organization from 1 to 500 employees. She brings robust …See details»